Skip to main
AUTL
AUTL logo

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics PLC is demonstrating promising advancements with its Obe-cel therapy, which recently received a positive regulatory decision supported by strong efficacy and safety data from the pivotal FELIX study. The company aims to enhance its financial performance by achieving gross margins of 60-70% through increased manufacturing utilization and process enhancements, signaling a commitment to operational efficiency. Additionally, the favorable safety profile of Aucazyl positions it competitively in the market, potentially establishing it as the preferred CAR-T therapy for certain cancer indications.

Bears say

Autolus Therapeutics faces a challenging outlook due to anticipated flat sales for the third quarter of 2025, attributed to changes in CMS reimbursement policies, which may hinder revenue growth in the short term. Furthermore, the company's production of CAR-T therapeutics is projected to fall short of forecasts, raising concerns about its ability to meet market demands. Additionally, the presence of severe adverse events associated with its therapies, such as cytokine release syndrome and neurotoxicity, could further restrict market acceptance and patient utilization of Autolus’ products.

Autolus Therapeutics (AUTL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Autolus Therapeutics (AUTL) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.